| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
The viability of A549, NCI-H1299, and HepaRG cells is drastically reduced in a dose-quantitative manner by polyphyllin VI (0-16 μM; 48 hours) [1][2]. The percentage of A549 and NCI-H1299 cells in the G2/M phase is dose-wise considerably increased by polyphyllin VI (0.5-2 μM-1 μM; 24 hours) [1]. HepaRG cells are arrested in the S phase for 24 hours by polyphyllin VI (0-12 μM-1 μM) [2]. In a 24-hour period, Polyphyllin VI (0–6 μM–1 μM) stimulates the NLRP3 signalosome [3]. Through the ROS/NF-κB pathway, Polyphyllin VI (0-6 μM-1 μM; 24 hours) detects A549 and NCI.[3]
|
|---|---|
| ln Vivo |
Lung cancer xenograft growth is inhibited by polyphyllin VI (2-4 mg/kg; intraperitoneally; 5 times per week for 4 weeks) [1]. Intraperitoneal injection of Polyphyllin VI (2.5–10 mg/kg) administered over a 10-day period
|
| Cell Assay |
Cell viability assay[1][3]
Cell Types: A549, NCI-H1299 and HepaRG cell Tested Concentrations: 0 μM, 2.5 μM, 5.0 μM, 7.5 μM, 10 μM, -H1299 cell pyroptosis[3]. 12.5 μM (A549, NCI-H1299), 0 μM, 2 μM, 4.0 μM, 6.0 μM, 8.0 μM, 10.0 μM, 12.0 μM, 16.0 μM (HepaRG) Incubation Duration: 48 hrs (hours) (A549, NCI-H1299), 24 h and 48 h (HepaRG) Experimental Results: the IC50 value of NCI-H1299 cells after treatment for 48 hrs (hours) was 1.87±0.09 μM, and that of A549 was 1.59±0.12 μM[1]. Studies have shown that HepaRG cell viability diminished by 88.90% to 1.07% after 24 hrs (hours) and by 79.06% to 0.71% after 48 hrs (hours) [2]. Cell viability determination [1] Cell Types: A549, NCI-H1299 cell Tested Concentrations: 0.5 μM, 1.0 μM, 2.0 μM Incubation Duration: 24 h Experimental Results: The G2/M phase of A549 cells was 25.14%±3.31%, 28.40 0.5, respectively. After 24 hrs (hours) of treatment with 1 and 2 μM, NCI-H1299 cells were %±4.63%, 42.66%±1.30% and 27.99%±4.68%, 30.24%±3.61% and 38.51%±5.10%, respectively. Cell cycle analysis [2] Cell Types: HepaRG Cell Tested Concentrations: 0 μ |
| Animal Protocol |
Animal/Disease Models: A549 tumor xenografts were inoculated subcutaneously (sc) (sc) into the right flank of nude mice [1]
Doses: 2 mg/kg, 3 mg/kg, ) NLRP3 inflammasome is activated in nude mice with A549 tumors [3]. 4 mg/kg Route of Administration: intraperitoneal (ip) injection Experimental Results: After treatment with 2 mg/kg, 3 mg/kg and 4 mg/kg, the tumor volume was diminished to 25.63%, 41.71% and 40.41% respectively. Animal/Disease Models: A549 tumor xenograft tumors were inoculated subcutaneously (sc) (sc) into the right flank of nude mice [3] Doses: 2.5 mg/kg, 5 mg/kg, 10 mg/kg Route of Administration: intraperitoneal (ip) injection Experimental Results: NLRP3, NLRP3 The expression of caspase-1, IL-1β and GSDMD all demonstrated a dose-increasing trend. |
| References |
|
| Additional Infomation |
Polyphyllin VI is a steroid saponin.
|
| Molecular Formula |
C39H62O13
|
|---|---|
| Molecular Weight |
738.9018
|
| Exact Mass |
738.419
|
| CAS # |
55916-51-3
|
| Related CAS # |
55916-51-3
|
| PubChem CID |
10417550
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
871.2±65.0 °C at 760 mmHg
|
| Flash Point |
480.7±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.616
|
| LogP |
6.09
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
52
|
| Complexity |
1370
|
| Defined Atom Stereocenter Count |
21
|
| SMILES |
C[C@@H]1CC[C@@]2([C@H]([C@]3([C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)C)C)O)C)OC1
|
| InChi Key |
WHWWQGPCTUQCMN-JDDKMXSSSA-N
|
| InChi Code |
InChI=1S/C39H62O13/c1-18-8-13-38(47-17-18)20(3)39(46)27(52-38)15-25-23-7-6-21-14-22(9-11-36(21,4)24(23)10-12-37(25,39)5)49-35-33(31(44)29(42)26(16-40)50-35)51-34-32(45)30(43)28(41)19(2)48-34/h6,18-20,22-35,40-46H,7-17H2,1-5H3/t18-,19+,20-,22+,23-,24+,25+,26-,27+,28+,29-,30-,31+,32-,33-,34+,35-,36+,37+,38-,39-/m1/s1
|
| Chemical Name |
(2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(1R,2S,4S,5'R,6R,7S,8S,9S,12S,13R,16S)-8-hydroxy-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~135.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (1.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (1.35 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (1.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3534 mL | 6.7668 mL | 13.5336 mL | |
| 5 mM | 0.2707 mL | 1.3534 mL | 2.7067 mL | |
| 10 mM | 0.1353 mL | 0.6767 mL | 1.3534 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
